Get the Stockscreener App
44.93
4.20%
1.81
After Hours:
44.71
-0.22
-0.49%
Sionna Therapeutics Inc stock is traded at $44.93, with a volume of 622.93K.
It is up +4.20% in the last 24 hours and up +27.03% over the past month.
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
See More
Previous Close:
$43.12
Open:
$43.67
24h Volume:
622.93K
Relative Volume:
1.46
Market Cap:
$2.03B
Revenue:
-
Net Income/Loss:
$-85.57M
P/E Ratio:
-23.44
EPS:
-1.9166
Net Cash Flow:
$-72.14M
1W Performance:
+2.14%
1M Performance:
+27.03%
6M Performance:
+3.98%
1Y Performance:
+114.36%
1-Day Range:
$43.00
$46.64
1-Week Range:
$40.92
$46.64
52-Week Range:
$16.38
$48.45
Sionna Therapeutics Inc Stock (SION) Company Profile
Name
Sionna Therapeutics Inc
Sector
Industry
Phone
617-819-2020
Address
21 HICKORY DRIVE, SUITE 500, WALTHAM
Compare SION vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SION
Sionna Therapeutics Inc
|
44.93 | 1.95B | 0 | -85.57M | -72.14M | -1.9166 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Sionna Therapeutics Inc Stock (SION) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-26 | Initiated | Citizens | Mkt Outperform |
| Dec-01-25 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
| Nov-19-25 | Initiated | BTIG Research | Buy |
| Sep-03-25 | Initiated | RBC Capital Mkts | Sector Perform |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| Mar-04-25 | Initiated | Guggenheim | Buy |
| Mar-04-25 | Initiated | Stifel | Buy |
| Mar-04-25 | Initiated | TD Cowen | Buy |
View All
Sionna Therapeutics Inc Stock (SION) Latest News
ETFs Investing in Sionna Therapeutics, Inc. Stocks - TradingView
SIONSionna Therapeutics Inc Options - Finviz
Sionna Therapeutics director Thompson sells $5.27m in stock - Investing.com
Form 4 Sionna Therapeutics Inc For: 2 July By Investing.com - Investing.com Canada
Sionna Therapeutics (SION) 10K Form and Latest SEC Filings 2026 - MarketBeat
Enterprise value to EBITDA forward of Sionna Therapeutics, Inc. – NASDAQ:SION - TradingView
Enterprise value to EBIT forward of Sionna Therapeutics, Inc. – NASDAQ:SION - TradingView
Enterprise value to revenue forward of Sionna Therapeutics, Inc. – NASDAQ:SION - TradingView
Price to earnings forward of Sionna Therapeutics, Inc. – NASDAQ:SION - TradingView
Price to sales forward of Sionna Therapeutics, Inc. – NASDAQ:SION - TradingView
Sionna Therapeutics: NBD1 Stabilization Could Redefine Cystic Fibrosis Treatment (SION) - Seeking Alpha
Sionna Therapeutics, Inc.(NasdaqGM: SION) dropped from Russell 3000E Index - marketscreener.com
Sionna Therapeutics, Inc.(NasdaqGM: SION) dropped from Russell Microcap Index - marketscreener.com
Sionna Therapeutics, Inc. Actuals & Estimates (NASDAQ:SION) - TradingView
SION Forecast — Price Target — Prediction for 2027 - TradingView
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Sionna Therapeutics, Inc. (SION) and Crescent Biopharma (CBIO) - The Globe and Mail
Citizens reiterates Sionna Therapeutics stock rating ahead of summer data By Investing.com - Investing.com Nigeria
Sionna Therapeutics: Buy Rating Reiterated on NBD1-Focused CF Strategy; $60 Price Target Maintained - TipRanks
Sionna Stockholders Reelect Directors, Ratify Deloitte as Auditor - The Globe and Mail
SION Q1 2026 Earnings: Wider Loss Surprises as Clinical Progress ContinuesFinal Results - newsline.com
Sionna Therapeutics - The Business Journals
Assessing Sionna Therapeutics (SION) Valuation After A Mixed Period For Recent Share Price Returns - Yahoo Finance
Transcript : Sionna Therapeutics, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-10-2026 10 - marketscreener.com
Sionna Therapeutics (SION) Gains 1.81% as Biotech Sentiment ImprovesBeta Neutral Pair - newsline.com
SION Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Faces Investor SkepticismGrowth Acceleration Report - newsline.com
Sionna Therapeutics (SION) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Biotech Sionna Therapeutics at Jefferies and Goldman Sachs in June - Stock Titan
Sionna Therapeutics director Peter Thompson sells $4,493 of shares - Investing.com India
Sionna Therapeutics director Peter Thompson sells $4,493 of shares By Investing.com - Investing.com South Africa
OrbiMed Advisors, director, sells $4,493 in Sionna Therapeutics stock - Investing.com
OrbiMed Advisors, director, sells $4,493 in Sionna Therapeutics stock By Investing.com - Investing.com UK
Form 144 | Sionna Therapeutics(SION.US) Insider Proposes to Sell 46.33 Million in Common Stocks - Moomoo
Sionna Therapeutics (SION) Sees Slight Decline Amidst Key Support TestPre-Earnings Momentum - The Legal Advocate
Sionna Therapeutics (SION) Edges Higher as Biotech Sentiment Improves — Testing Key ResistanceAdvance Decline Volume - thelegaladvocate.com
Sionna Therapeutics to Participate in Upcoming June 2026 Investor Conferences - markets.businessinsider.com
SION Reiterates by Citizens -- Price Target Maintained at $63 - GuruFocus
Stifel Nicolaus Sticks to Their Buy Rating for Sionna Therapeutics, Inc. (SION) - The Globe and Mail
Stifel reiterates Buy on Sionna Therapeutics stock ahead of data - Investing.com
Stifel reiterates Buy on Sionna Therapeutics stock ahead of data By Investing.com - Investing.com Canada
Citizens reiterates Sionna Therapeutics stock rating on CF treatment potential By Investing.com - Investing.com Canada
SION Q1 2026 Earnings: Clinical-Stage Biotech Misses Estimates with Wider Net LossEarnings Growth Forecast - newsline.com
Number of shareholders of Sionna Therapeutics, Inc. – NASDAQ:SION - TradingView
A Quick Look at Today's Ratings for Sionna Therapeutics(SION.US), With a Forecast Between $50 to $63 - Moomoo
Freedom Broker downgrades Sionna Therapeutics (SION) - MSN
Sionna Therapeutics Cut to Hold From Buy by Freedom Broker - Moomoo
SION: Phase II data for two NBD1 stabilizers in CF expected this summer, aiming for superior efficacy - TradingView
Sionna Therapeutics Price Target Maintained With a $38.00/Share by Freedom Broker - Moomoo
Sionna Therapeutics Inc Stock (SION) Financials Data
Revenue
Net Income
Cash Flow
EPS
Sionna Therapeutics Inc Stock (SION) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Thompson Peter A. | Director |
Jun 30 '26 |
Sale |
45.50 |
115,844 |
5,270,902 |
2,555,877 |
| ORBIMED ADVISORS LLC | Director |
Jun 30 '26 |
Sale |
45.50 |
115,844 |
5,270,902 |
2,555,877 |
| Thompson Peter A. | Director |
May 27 '26 |
Sale |
44.49 |
101 |
4,493 |
2,671,721 |
| ORBIMED ADVISORS LLC | Director |
May 27 '26 |
Sale |
44.49 |
101 |
4,493 |
2,671,721 |
1.17%
2.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):